Article thumbnail

Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients

By Savina Nodari, Geoffrey T Jao and Jun R Chiong


Hyponatremia is an electrolyte disorder frequently observed in several clinical settings and common in hospitalized patients with decompensated heart failure (HF). It is caused by deregulation of arginine vasopressin (AVP) homeostasis associated with water retention in hypervolemic or in euvolemic states. While hypervolemic hypotonic hyponatremia is also seen in advanced liver cirrhosis, renal failure, and nephrotic syndrome, the bulk of evidence associating this electrolyte disorder to increasing morbidity and mortality can be found in the HF literature. Hospitalized HF patients with low serum sodium concentration have lower short-term and long-term survival, longer hospital stay and increased readmission rates. Conventional therapeutic approaches, ie, restriction of fluid intake, saline and diuretics, can be effective, but often the results are unpredictable. Recent clinical trials have demonstrated the effectiveness of nonpeptide AVP receptor antagonists (vaptans) in the treatment of hyponatremia. The vaptans induce aquaresis, an electrolyte-sparing excretion of free water resulting in the correction of serum sodium concentrations and plasma osmolality, without activation of the renin-angiotensin-aldosterone system (RAAS) or changes in renal function and blood pressure. Further prospective studies in a selected congestive HF population with hyponatremia, using clinical-status titrated dose of tolvaptan, are needed to determine whether serum sodium normalization will be translated into a better long-term prognosis. This review will focus on recent clinical trials with tolvaptan, an oral V2 receptor antagonist, in HF patients. The ability of tolvaptan to safely increase serum sodium concentration without activating the RAAS or compromising renal function and electrolyte balance makes it an attractive agent for treating hyponatremic HF patients

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1999). 7-Chloro-5-hydroxy-1-[2-methyl4-(2-methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active non-peptide arginine vasopressin V2 receptor antagonist. Bio org Med Chem.
  2. (1995). A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure.
  3. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo controlled trial.
  4. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
  5. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure.
  6. (2003). Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Act.
  7. (1995). Aquaretic effect of a potent, orally active, non peptide V2 antagonist in men. J Pharmacol Exp Ther.
  8. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
  9. (2007). Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med.
  10. (1998). Diuretic Therapy.
  11. (2003). Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: Long-term effects. Am Heart J.
  12. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
  13. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
  14. et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
  15. Evaluation and management of hypo-osmolality in hospitalized patients.
  16. (2009). FDA labeling information. FDA web site.
  17. for the conivaptan study group. Efficacy and safety of oral conivaptan: A V1a/V2 vasopressin receptor antagonist, in patients with advanced heart failure.
  18. (2005). Hemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial.
  19. (2005). Hyponatremia and heart failure – pathophysiology and implications. Congest Heart Fail.
  20. Hyponatremia and hypernatremia: a systematic approach to causes and their correction. Postgrad Med.
  21. (2004). Management of hyponatremia. Am Fam Physician.
  22. Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int Suppl.
  23. Mechanisms, risks, and new treatment options for hyponatremia.
  24. Multicenter randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
  25. (2009). Nat Rev Drug Discov.
  26. OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.
  27. Osmotic and nonosmotic control of vasopressin release.
  28. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, an non-peptide AV antagonist and furosemide or hydrochlorothiazide.
  29. (1997). Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1a and V2 receptor antagonist, in dogs.
  30. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.
  31. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure.
  32. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.
  33. (2005). Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan
  34. Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction.
  35. (2006). Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med.
  36. (2009). Study: Treatment of Hyponatremia Based on Lixivaptan
  37. (2009). The treatment of hyponatremia. Semin Nephrol.
  38. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias.
  39. Tolvaptan investigators. Vasopressin receptor blockade in patients with congestive heart failure: results from a randomized, double-blind study.
  40. Tolvaptan Investigators. Vasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.
  41. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
  42. (2009). Treatment options for hyponatremia in heart failure. Heart Fail Rev.
  43. Vasopressin antagonism in heart failure.
  44. Vasopressin V2 receptor antagonists.
  45. (2006). Vasopressin2-receptor antagonism augments water excretion without changes in renal hemodynamic or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol.